|
Cardioline Acquires Cardios, Creating a Comprehensive Global Leader in Cardiac Diagnostics
hits:48 Date:05/02/26
* Strategic combination unites Cardioline’s global reach and proven cardiac technology with Cardios’s decades of clinical expertise in Holter monitoring and ABPM
TRENTO, IT, April 30, 2026 / Biotech Newswire / -- Cardioline, a globally recognized leader in cardiac diagnostics and a pioneer in Telecardiology — delivering connected, remote cardiac care solutions to clinicians and patients across more than 85 countries — today announced the successful acquisition of Cardios (São Paulo, Brazil) from Halma. Cardios is a highly respected innovator in Holter monitoring and ambulatory blood pressure monitoring (ABPM) with a decades-long track record of clinical reliability in Brazil. The transaction, supported by ARCHIMED, marks a transformative milestone for both organizations — accelerating Cardioline’s telecardiology strategy and signalling a new chapter in the advancement of comprehensive, connected, and patient-centered cardiac diagnostics worldwide.
The acquisition brings together two organizations whose complementary strengths span the full cardiac diagnostic journey. Cardioline’s already internationally established full portfolio will be further complemented with Cardios’s specialized regional expertise in Holter and ABPM technologies. Together, the combined entity is positioned to deliver a broader, more integrated suite of cardiac diagnostic solutions to physicians, healthcare institutions, and patients across global markets.
ARCHIMED, the specialist healthcare private equity firm and majority shareholder of Cardioline, played a central role in enabling this transaction. The acquisition reflects ARCHIMED’s continued commitment to building leading, scaled platforms in medtech and healthcare services, and furthers Cardioline’s growth strategy under ARCHIMED’s ownership. This milestone equally reflects the strong foundation that Halma has built at Cardios over the years — their stewardship has produced a business of exceptional clinical quality and commercial strength, and Cardioline is proud to continue building on that legacy.
“This acquisition is an exciting moment for Cardioline and a clear expression of our vision: to power a better cardiac care globally. Cardios has earned an exceptional reputation for precision and reliability over decades, and their deep expertise in Holter and ABPM is the perfect complement to our global portfolio. Together, we are creating a truly end-to-end solution that supports every step of the cardiac care pathway.
This transaction also significantly strengthens Cardioline’s leadership position in telemedicine. Beyond the product synergies, this acquisition opens a meaningful new geographic hub for Cardioline, expanding our presence and commercial reach into markets where Cardios has built strong, trusted relationships. This is precisely the kind of strategic growth — clinically grounded, geographically expansive, and deeply aligned in values — that we set out to achieve with the support of ARCHIMED. We are proud to welcome the Cardios team into the Cardioline family.” — Luis Meireles, CEO, Cardioline
“This integration represents a strategic leap for Cardios’s portfolio, which now incorporates Cardioline’s proven solutions, specifically in stress test systems and electrocardiography, increasing our capability to offer a complete care across the clinical journey. By combining Cardioline’s global reach with the clinical expertise, market proximity, and the reliability built by Cardios in Holter and ABPM over decades, we strengthen our shared goal of redefining standards in cardiac diagnostics and generating a positive, lasting impact for physicians, healthcare institutions, and patients. Together we may transform innovation into solutions that make the difference saving lives” — Erica Chriguer, Cardios
Semantic keywords: Diagnostic Techniques and Procedures; Blood Pressure Monitoring, Ambulatory; Electrocardiography, Ambulatory; Cardioline; Cardios; acquisition; cardiac diagnostics; telecardiology; remote cardiac care; Holter monitoring; ambulatory blood pressure monitoring; ABPM; cardiac technology; connected cardiac care; patient-centered cardiac diagnostics; telemedicine; electrocardiography; healthcare institutions; physicians; ARCHIMED; healthcare private equity; medtech; healthcare services
About Cardioline
Cardioline is a globally recognized manufacturer of cardiac diagnostic equipment, specializing in ECG systems, stress testing platforms, and integrated cardiology solutions. With a legacy of innovation spanning decades, Cardioline serves healthcare professionals and institutions across more than 85 countries globally, delivering technology that advances clinical precision and patient outcomes. Cardioline is an ARCHIMED company.
About Cardios
Cardios is a leading provider of Holter monitoring and ambulatory blood pressure monitoring (ABPM) solutions, built on decades of clinical expertise and a trusted reputation among healthcare providers. Known for their reliability and proximity to the clinical market, Cardios has become a reference in long-term cardiac monitoring for patients and institutions across Brazil.
About ARCHIMED
With offices in Europe, North America and Asia, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Animal & Environmental Health, Biopharma Products, Consumer Health, Diagnostics, Healthcare IT, Life Science Tools & Services and MedTech. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages €9 billion across its various funds. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EURÊKA Foundation.
Contact
Cardioline
Johnna Hafner
J.hafner@cardioline.com
|
中文
